Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCR-PH1 in primary hyperoxaluria type 1
NCT02795325Phase 1Terminated
- Sponsor
- Novo Nordisk
- Start
- May 2016
- Primary completion
- Oct 2016
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of DCR-PH1 in Primary Hyperoxaluria Type 1 (PH1) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Adverse Events at 29 days. Started May 2016; status: terminated.
02
Drugs
DCR-PH1
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT02795325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795325.